Together, our data demonstrate that nucleolar FAK promotes ribosome biogenesis and protein synthesis to drive thyroid cancer growth and survival, and thus presents a promising therapeutic target to treat thyroid and other FAK-driven cancers. This evidence concerns the gene PTK2 and thyroid gland carcinoma.